Table 2 Toxicities during cycle 1
From: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Toxicity | Grade 1–2 | Grade 3a | Grade 4 | Unknown grade | Total |
|---|---|---|---|---|---|
ALT increase | 6 (11.8%) | 3 (5.9%) | 9 (17.6%) | ||
AST increase | 8 (15.7%) | 2 (3.9%) | 10 (19.6%) | ||
GGT increase | 2 (3.9%) | 1 (2.0%) | 1 (2.0%) | 4 (7.8%) | |
Hyperbilirubinemia | 1 (2.0%) | 1 (2.0%) | |||
Fever | 9 (17.6%) | 9 (17.6%) | |||
Febrile neutropenia | 2 (3.9%) | 6 (11.8%) | 8 (15.7%) | ||
Infection | 4 (7.8%) | 8 (15.7%) | 2 (3.9%) | 1 (2.0%) | 15 (29.4%) |
Bone pain | 3 (5.9%) | 1 (2.0%) | 4 (7.8%) | ||
Infusion reaction | 2 (3.9%) | 2 (3.9%) | |||
Vomiting | 2 (3.9%) | 1 (2.0%) | 3 (5.9%) | ||
Diarrhea | 1 (2.0%) | 1 (2.0%) | 2 (3.9%) | ||
Tumor lysis syndrome | 2 (3.9%) | 2 (3.9%) | |||
Bleeding | 1 (2.0%) | 1 (2.0%) | 2 (3.9%) | ||
Electrolyte disturbances | 7 (13.7%) | 3 (5.9%)b | 10 (19.6%) |
